Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

Scandinavian Biopharma Distribution logo

Scandinavian Biopharma Distribution

Our ETEC vaccine will be an important tool to battle diarrheal disease

Being healthy is the most important thing in life and to prevent disease is something we all strive for. Vaccination is one of the most effective and cost-effective medical interventions available.

Worldwide, diarrheal disease is a leading cause of childhood death in developing countries. Enterotoxigenic Escherichia coli (ETEC) infection is one of the most common causes of diarrhea in developing countries, responsible for around 400 million cases and hundreds of thousands of deaths each year. Children under the age of five years are most affected.

ETEC bacteria also cause diarrhea in nearly one in two travelers to these areas, and over 10% of ill travelers may go on to develop functional bowel disorders during convalescence. Today there is no ETEC vaccine available to address these unmet medical needs.

Scandinavian Biopharma is a Swedish research-based biotech company. The company is a leading distributor of vaccines and immunoglobulins to the Nordic market. Together with the American non-profit organization, PATH Vaccine Solutions and researchers at the University of Gothenburg, the company is developing a new ETEC vaccine.

Prevention through vaccination is the best way to protect children against the leading causes of severe diarrhoea. Vaccines may even reduce malnutrition and developmental delays associated with severe diarrhoea in children. Therefor the development of an ETEC vaccine is critical, especially for developing countries where diarrheal diseases are most prevalent and the medical infrastructure is limited. Here medical care and treatment is often limited and hard to access, and diarrhea can be deadly. A vaccine against ETEC could save hundreds of thousands of children every year.

Our vaccine candidate ETVAX is the most advanced ETEC vaccine. In several clinical trials the vaccine has showed impressive results, been proven safe and shown a much better ability to activate the immune system than expected.

During the beginning of this year the last patient out of 450 was enrolled in a Phase I/II study in Dhaka, Bangladesh where our ETEC vaccine was tested for safety and immunogenicity in different age groups down to 6 months young infants. Samples from the trial are now being analysed and later this year data will be unblinded. This is the first important step toward showing that our vaccine will improve children's chances of winning the fight against diarrheal disease.

We have this year also started a phase IIB study in approximately 800 Finnish travellers, where safety, analytical methods and the vaccine’s protective effect will be evaluated in a travel population. The study is involving researchers from Helsinki University, Johns Hopkins University in Baltimore and Gothenburg University. With this study, conducted in Benin in Africa, we hope to provide evidence that the vaccine is preventing diarrhoea caused by ETEC in travellers’.

Our vision is to successfully develop a vaccine with the potential to save hundreds of thousands lives in the Third World, but that also can save the holiday for millions of travelers.

A proof that we are on the right track and that our vaccine is of very high standard is that we are supported by PATH in USA and EU Research and Innovation program Horizon 2020 in Europe.  

Get in touch with us!

Visit us

Scandinavian Biopharma Distribution

Industrivägen 1,

SE-171 48 Solna,

Sweden

Send us mail

Our published articles

No items found.
Date
Title
Category
No articles found.
Scandinavian Biopharma Distribution

Scandinavian Biopharma Distribution

Our ETEC vaccine will be an important tool to battle diarrheal disease

Being healthy is the most important thing in life and to prevent disease is something we all strive for. Vaccination is one of the most effective and cost-effective medical interventions available.

Worldwide, diarrheal disease is a leading cause of childhood death in developing countries. Enterotoxigenic Escherichia coli (ETEC) infection is one of the most common causes of diarrhea in developing countries, responsible for around 400 million cases and hundreds of thousands of deaths each year. Children under the age of five years are most affected.

ETEC bacteria also cause diarrhea in nearly one in two travelers to these areas, and over 10% of ill travelers may go on to develop functional bowel disorders during convalescence. Today there is no ETEC vaccine available to address these unmet medical needs.

Scandinavian Biopharma is a Swedish research-based biotech company. The company is a leading distributor of vaccines and immunoglobulins to the Nordic market. Together with the American non-profit organization, PATH Vaccine Solutions and researchers at the University of Gothenburg, the company is developing a new ETEC vaccine.

Prevention through vaccination is the best way to protect children against the leading causes of severe diarrhoea. Vaccines may even reduce malnutrition and developmental delays associated with severe diarrhoea in children. Therefor the development of an ETEC vaccine is critical, especially for developing countries where diarrheal diseases are most prevalent and the medical infrastructure is limited. Here medical care and treatment is often limited and hard to access, and diarrhea can be deadly. A vaccine against ETEC could save hundreds of thousands of children every year.

Our vaccine candidate ETVAX is the most advanced ETEC vaccine. In several clinical trials the vaccine has showed impressive results, been proven safe and shown a much better ability to activate the immune system than expected.

During the beginning of this year the last patient out of 450 was enrolled in a Phase I/II study in Dhaka, Bangladesh where our ETEC vaccine was tested for safety and immunogenicity in different age groups down to 6 months young infants. Samples from the trial are now being analysed and later this year data will be unblinded. This is the first important step toward showing that our vaccine will improve children's chances of winning the fight against diarrheal disease.

We have this year also started a phase IIB study in approximately 800 Finnish travellers, where safety, analytical methods and the vaccine’s protective effect will be evaluated in a travel population. The study is involving researchers from Helsinki University, Johns Hopkins University in Baltimore and Gothenburg University. With this study, conducted in Benin in Africa, we hope to provide evidence that the vaccine is preventing diarrhoea caused by ETEC in travellers’.

Our vision is to successfully develop a vaccine with the potential to save hundreds of thousands lives in the Third World, but that also can save the holiday for millions of travelers.

A proof that we are on the right track and that our vaccine is of very high standard is that we are supported by PATH in USA and EU Research and Innovation program Horizon 2020 in Europe.  

Get in touch with us!

Visit us

Scandinavian Biopharma Distribution

Industrivägen 1,

SE-171 48 Solna,

Sweden

Send us mail

Our published articles

No items found.
Date
Title
Category
No articles found.